Transcept Pharmaceuticals is a specialty pharmaceutical company engaged in developing and commercializing proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo (zolpidem tartrate) sublingual tablet C-IV is the company’s first FDA-approved product. Commercialization and development rights for Intermezzo in the U.S. are held by Purdue Pharma. For more information, visit the company’s Web site at www.transcept.com.
The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.
Let us hear your thoughts below: